CD163 and breast carcinoma: Our findings demonstrate that high PDLIM2 expression in breast cancer is predominantly associated with higher levels of CD163- and CD206-positive macrophages that likely represent the M2 subset, whereas the expression of T lymphocytic markers is not uniquely associated with PDLIM2 expression.